Australia: National Reconstruction Fund Corporation takes AUD 54 million equity stake in Synchron brain-computer interface devices

Mechanism

NRFC — the AUD 15 billion Commonwealth financing vehicle established to rebuild sovereign industrial capability — took a AUD 54 million equity position inside Synchron's ~AUD 305-308 million (~USD 200 million) Series D funding round, announced 7 November 2025. Synchron, founded in Melbourne in 2012 (Tom Oxley, Nicholas Opie, Rahul Sharma) and now headquartered in the US (Brooklyn NY / Redwood City CA), develops the Stentrode — a catheter-delivered brain-computer interface implanted into a blood vessel adjacent to the motor cortex, avoiding open-skull neurosurgery required by rivals such as Neuralink. Co-investors in the round included Qatar Investment Authority, In-Q-Tel, Double Point Ventures, K5 Global, 3C AGI, T.Rx Capital and Protocol Labs.

NRFC CEO David Gall framed the deal as commercialising Australian-founded innovation and building "sovereign medical capability" and skilled domestic jobs, even though Synchron's operational and regulatory center of gravity (FDA approval pathway, US clinical/commercial base) sits offshore. The funding is earmarked for completing pivotal clinical trials and pursuing FDA marketing approval, plus establishing an Australian commercial/clinical-trial hub for the device.

GTA's state-act record for this deal (95169, "Equity stake") has a companion state-act entry (95168/95169-adjacent intervention 150489, "Local value added incentive") logged against the same underlying transaction — GTA's classification scheme tags the single AUD 54 million commitment under two intervention types; this filing treats it as one action.

Downstream implications

• Extends NRFC's pattern (alongside 2025-12-02-australia-nrfc-intellihub-smart-meter-loan and

2025-12-08-australia-nrfc-arnotts-group-refinancing) of taking minority positions inside externally-led financing rounds for already-scaled private companies, rather than seeding greenfield manufacturing — here extending that pattern into medical-device/biotech equity for the first time.

• Sovereign strategic-tech competition angle: Synchron is widely covered as a commercial

BCI rival to Neuralink; an Australian sovereign fund taking equity in a US-domiciled, Qatar/US-co-invested BCI company blurs the domestic-industrial-policy vs outbound-strategic-investment framing that defines NRFC's mandate.

Open questions

• No public disclosure of what board rights, information rights, or follow-on protections NRFC

holds as a minority equity investor in a foreign-domiciled company.

• Unclear how much of the AUD 54 million is contractually tied to onshoring clinical-trial or

manufacturing activity in Australia versus being a passive financial equity stake in a US company's global raise.